{
    "id": 2527,
    "fullName": "KRAS G12A",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "KRAS G12A is a hotspot mutation that lies within a GTP-binding region of the Kras protein (UniProt.org). G12A results in decreased Kras GTPase activity and activation of ERK and PI3K signaling in cell culture (PMID: 23455880, PMID: 26037647, PMID: 32079091).",
            "references": [
                {
                    "id": 3052,
                    "pubMedId": 26037647,
                    "title": "Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26037647"
                },
                {
                    "id": 26,
                    "pubMedId": 23455880,
                    "title": "KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23455880"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 18061,
                    "pubMedId": 32079091,
                    "title": "Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32079091"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3845,
        "geneSymbol": "KRAS",
        "terms": [
            "KRAS",
            "'C-K-RAS",
            "C-K-RAS",
            "c-Ki-ras",
            "c-Ki-ras2",
            "CFC2",
            "K-Ras",
            "K-Ras 2",
            "K-RAS2A",
            "K-RAS2B",
            "K-RAS4A",
            "K-RAS4B",
            "KI-RAS",
            "KRAS1",
            "KRAS2",
            "NS",
            "NS3",
            "OES",
            "RALD",
            "RASK2"
        ]
    },
    "variant": "G12A",
    "createDate": "11/03/2014",
    "updateDate": "03/09/2020",
    "referenceTranscriptCoordinates": {
        "id": 157045,
        "transcript": "NM_033360",
        "gDna": "chr12:g.25245350C>G",
        "cDna": "c.35G>C",
        "protein": "p.G12A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4935,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells harboring KRAS G12A in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 2381,
                "profileName": "KRAS G12A"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3012,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Farydak (panobinostat) induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMID: 19490892, PMID: 22693356).",
            "molecularProfile": {
                "id": 2381,
                "profileName": "KRAS G12A"
            },
            "therapy": {
                "id": 1080,
                "therapyName": "Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1018,
                    "pubMedId": 22693356,
                    "title": "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22693356"
                },
                {
                    "id": 2128,
                    "pubMedId": 19490892,
                    "title": "Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19490892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15995,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited proliferation of lung cancer cell lines harboring KRAS G12A in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 2381,
                "profileName": "KRAS G12A"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4941,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring KRAS G12A were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 2381,
                "profileName": "KRAS G12A"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3011,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMID: 19490892, PMID: 22693356).",
            "molecularProfile": {
                "id": 2381,
                "profileName": "KRAS G12A"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1018,
                    "pubMedId": 22693356,
                    "title": "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22693356"
                },
                {
                    "id": 2128,
                    "pubMedId": 19490892,
                    "title": "Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19490892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12380,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with the combination of Gedatolisib (PF-05212384) and PD-0325901 resulted in an overall response rate of 11.1% (4/44) and clinical benefit rate of 16.3% (7/44) in patients with a variety of solid tumors, with three ovarian cancer patients harboring KRAS mutations (G12A, G12V, G13D, respectively) and one endometrial cancer patient harboring KRAS G12D achieved partial responses (PMID: 29067643; NCT01347866).",
            "molecularProfile": {
                "id": 2381,
                "profileName": "KRAS G12A"
            },
            "therapy": {
                "id": 3025,
                "therapyName": "Gedatolisib + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10357,
                    "pubMedId": 29067643,
                    "title": "A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29067643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4625,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited viability of non-small cell lung cancer cells harboring MAP3K9 E179K, along with concurrent KRAS G12A, in culture (PMID: 23836671).",
            "molecularProfile": {
                "id": 18655,
                "profileName": "KRAS G12A MAP3K9 E179K"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1133,
                    "pubMedId": 23836671,
                    "title": "Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23836671"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6514,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BI 885578 inhibited proliferation of colon carcinoma cell lines harboring IGF2 over expression and KRAS G12A in culture, and reduced tumor growth in xenograft models (PMID: 26438154).",
            "molecularProfile": {
                "id": 23605,
                "profileName": "IGF2 over exp KRAS G12A"
            },
            "therapy": {
                "id": 4132,
                "therapyName": "BI 885578",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5673,
                    "pubMedId": 26438154,
                    "title": "BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9029,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782).",
            "molecularProfile": {
                "id": 25935,
                "profileName": "KRAS G12A MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6878,
                    "pubMedId": 27196782,
                    "title": "In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7733,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MET amplified lung cancer cells harboring KRAS G12A were insensitive to SAR125844-mediated growth inhibition in culture (PMID: 25504634).",
            "molecularProfile": {
                "id": 25935,
                "profileName": "KRAS G12A MET amp"
            },
            "therapy": {
                "id": 2159,
                "therapyName": "SAR125844",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2009,
                    "pubMedId": 25504634,
                    "title": "The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25504634"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16589,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 18 weeks to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment, KRAS G12A was identified as an acquired mutation at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 31706,
                "profileName": "BRAF V600E KRAS G12A"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18711,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring LMNA-NTRK1 and NTRK1 G595R demonstrated liver progression while on treatment with LOXO-195 and was found via cell-free DNA (cfDNA) testing to have acquired KRAS G12A, however, upon liver ablation and further LOXO-195 treatment, subsequent cfDNA testing revealed loss of KRAS G12A, but acquisition of KRAS G12D (PMID: 31406350).",
            "molecularProfile": {
                "id": 33513,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A KRAS G12D"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18713,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring LMNA-NTRK1 and expressing KRAS G12A demonstrated resistance to treatment with Vitrakvi (larotrectinib) in culture (PMID: 31406350).",
            "molecularProfile": {
                "id": 33519,
                "profileName": "LMNA - NTRK1 KRAS G12A"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18714,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring LMNA-NTRK1 and NTRK1 G595R and expressing KRAS G12A demonstrated resistance to treatment with LOXO-195 in culture (PMID: 31406350).",
            "molecularProfile": {
                "id": 33523,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19124,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring LMNA-NTRK1, NTRK1 G595R, and KRAS G12A demonstrated progression when treated with the combination of LOXO-195 and Mekinist (trametinib), however, a patient-derived xenograft (PDX) model for this patient demonstrated inhibition of tumor growth (PMID: 31406350).",
            "molecularProfile": {
                "id": 33523,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A"
            },
            "therapy": {
                "id": 8914,
                "therapyName": "LOXO-195 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2381,
            "profileName": "KRAS G12A",
            "profileTreatmentApproaches": [
                {
                    "id": 15968,
                    "name": "AZD4785",
                    "profileName": "KRAS G12A"
                },
                {
                    "id": 15972,
                    "name": "PIK3CA inhibitor",
                    "profileName": "KRAS G12A"
                },
                {
                    "id": 15971,
                    "name": "RAS Inhibitor (Pan)",
                    "profileName": "KRAS G12A"
                },
                {
                    "id": 15973,
                    "name": "MEK2 Inhibitor",
                    "profileName": "KRAS G12A"
                },
                {
                    "id": 15970,
                    "name": "MEK1 Inhibitor",
                    "profileName": "KRAS G12A"
                },
                {
                    "id": 15967,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "KRAS G12A"
                },
                {
                    "id": 15969,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "KRAS G12A"
                }
            ]
        },
        {
            "id": 18655,
            "profileName": "KRAS G12A MAP3K9 E179K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23605,
            "profileName": "IGF2 over exp KRAS G12A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25935,
            "profileName": "KRAS G12A MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31706,
            "profileName": "BRAF V600E KRAS G12A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33513,
            "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33519,
            "profileName": "LMNA - NTRK1 KRAS G12A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33523,
            "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 157048,
            "transcript": "XM_006719069",
            "gDna": "chr12:g.25245350C>G",
            "cDna": "c.35G>C",
            "protein": "p.G12A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157045,
            "transcript": "NM_033360",
            "gDna": "chr12:g.25245350C>G",
            "cDna": "c.35G>C",
            "protein": "p.G12A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157046,
            "transcript": "XM_017019293",
            "gDna": "chr12:g.25245350C>G",
            "cDna": "c.35G>C",
            "protein": "p.G12A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157044,
            "transcript": "NM_004985",
            "gDna": "chr12:g.25245350C>G",
            "cDna": "c.35G>C",
            "protein": "p.G12A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157047,
            "transcript": "XM_011520653",
            "gDna": "chr12:g.25245350C>G",
            "cDna": "c.35G>C",
            "protein": "p.G12A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}